Is Imvexxy (estradiol) covered by Medicare Part D?
457 of 5,052 Medicare Part D plan offerings (9%) list Imvexxy on their 2026 formulary, most often on tier 3; 10.8% of the formularies that cover it require prior authorization. Part D spending on it was $14 million in 2024 for 9,858 people: what plans and patients paid at the pharmacy, before manufacturer rebates (CMS Part D Spending by Drug).
- Plans that cover it
- 9%
- 457 of 5,052 offerings; the median drug: 76%
- Usual tier
- Tier 3
- from tier 1 to tier 4
- Prior authorization
- 10.8%
- of formularies that cover it; the median drug: 1%
- Quantity limits
- 18.9%
- of formularies that cover it; the median drug: 30%
5.4% of the formularies that cover it require step therapy (trying another drug first).
Source: CMS Part D formulary file, 2026 second quarter: the formularies in use in 2026. A plan's 2027 formulary can differ; check your own plan's coverage in Medicare Plan Finder.
What does it cost under Part D in 2027?
- Your yearly cap in 2027
- Out-of-pocket spending on covered Part D drugs stops at $2,400 in 2027 ($2,100 in 2026); after that, you pay nothing for covered drugs for the rest of the year.
- The deductible
- A plan's drug deductible is at most $700 in 2027 ($615 in 2026); many plans charge less or none.
Source: CMS, Announcement of calendar year 2027 Part D parameters; Medicare.gov, “How much does Medicare drug coverage cost?” (read Oct. 7, 2026).
How much does Medicare spend on it?
Part D spending by year
9,858 people filled it under Part D in 2024, in 34,317 claims. The amounts are what plans and patients paid at the pharmacy, before manufacturer rebates.
Source: CMS Medicare Part D Spending by Drug, 2020 to 2024 (published June 2026). Row used: Imvexxy (Estradiol).
Which forms and strengths are counted?
- pack of 18 × estradiol 0.004 mg vaginal insert
- pack of 18 × estradiol 0.01 mg vaginal insert
- pack of 8 × estradiol 0.004 mg vaginal insert
- pack of 8 × estradiol 0.01 mg vaginal insert
Which other versions are listed?
The same ingredients under other names, each with its own coverage and spending.
- Estradiol100% of plan offerings
- Yuvafem (estradiol)81.7% of plan offerings
- Dotti (estradiol)76.7% of plan offerings
- Lyllana (estradiol)64.1% of plan offerings
- Estring (estradiol)62.6% of plan offerings
- Femring (estradiol)5.5% of plan offerings
- Climara (estradiol)2.6% of plan offerings
- Estrace (estradiol)2.3% of plan offerings
- Evamist (estradiol)0.9% of plan offerings
- Menostar (estradiol)0.5% of plan offerings
- Elestrin (estradiol)0.4% of plan offerings
- Minivelle (estradiol)0.3% of plan offerings
- Divigel (estradiol)under 0.1% of plan offerings
- Vagifem (estradiol)under 0.1% of plan offerings
What else should you check?
- Stand-alone drug plans for 2027Premiums and deductibles
- Drugs Medicare spends the most onThe 2024 spending list
- 2027 costs and limitsDeductibles and out-of-pocket limits
Data, not medical advice. Coverage is the share of plan formularies listing the drug; your plan's formulary, tier and pharmacy decide what you pay.